Constellation Pharmaceuticals develops drugs in the field of epigenetics focusing on selective regulators of its function.
Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science which is focused on selective regulators of epigenetic function, which are critical to controlling gene expression.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 20, 2019 | Post-IPO Debt | $40M | 1 | — | — | Detail |
Apr 9, 2018 | Series F | $100M | 1 | — | — | Detail |
Jul 1, 2017 | Series E | $48.50M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Hercules Capital | — | Post-IPO Debt |
University of California Investment Office | — | Series F |